Frontiers in Oncology (Feb 2023)

Correlation between Metabolite of Prostaglandin E2 and the incidence of colorectal adenomas

  • Jia Jiang,
  • Anjie Li,
  • Xiaolian Lai,
  • Hanqun Zhang,
  • Chonghong Wang,
  • Huimin Wang,
  • Libo Li,
  • Yuncong Liu,
  • Lu Xie,
  • Can Yang,
  • Cui Zhang,
  • Shuoyan Lu,
  • Yong Li

DOI
https://doi.org/10.3389/fonc.2023.1068469
Journal volume & issue
Vol. 13

Abstract

Read online

Colorectal cancer is a common malignancy, and the incidence and mortality rates continue to rise. An important factor in the emergence of inflammation-induced colorectal carcinogenesis is elevated cyclooxygenase-2. Prostaglandin E2 (PGE2) over-production is frequently equated with cyclooxygenase-2 gene over-expression. PGE2 can be assessed by measuring the level of prostaglandin’s main metabolite, PGE-M, in urine. Colorectal adenoma is a precancerous lesion that can lead to colorectal cancer. We conducted research to evaluate the association between urinary levels of the PGE-M and the risk of colorectal adenomas. In a western Chinese population, we identified 152 cases of adenoma and 152 controls patients without polyps. Adenoma cases were categorized into control, low-risk and high-risk groups. There was no significant change in PGE-M levels, between the control group and the low-risk adenoma group. In the high-risk group, the PGE-M levels were 23% higher than the control group. When compared to people with the lowest urine PGE-M levels (first quartile), people with greater urinary PGE-M levels had a higher chance of developing high-risk colorectal adenomas, with an adjusted odds ratio (95% CI) of 1.65 (0.76-3.57) in the fourth quartile group, (p= 0.013). We conclude urinary PGE-M is associated with the risk of developing high-risk adenomas. Urinary PGE-M level may be used as a non-invasive indicator for estimating cancer risk.

Keywords